23rd Global Cardio Vascular Clinical Trialists (CVCT) Forum, 7-9 December 2026, Washington DC
Read more at this link
PH Update 2026 – Gateway to the 8th World Symposium, Sheraton Ann Arbor, Michigan, USA, October 2, 2026
The PH Update 2026 – Gateway to the 8th World Symposium will bring together experts in Pulmonary Hypertension for a day of scientific discussion, clinical updates and perspectives toward the 8th World Symposium on Pulmonary Hypertension. Click here for programme and to register
Patient advocate Natalia Maeva at the European Respiratory Society (ERS) Presidential Summit, Warsaw 2026
Natalia Maeva, a patient advocate for pulmonary hypertension, attended the European Respiratory Society (ERS) Presidential Summit in Warsaw in June 2026, participating in sessions on early detection, air quality, tobacco control, climate change and lung health. Having had her own life transformed by access to specialised treatment and lung transplantation, she found the discussions on
American Thoracic Society (ATS) annual conference 2026 discussions on AI, Innovation, and Humanism in medicine, American Medical Journal, July 1, 2026
The American Thoracic Society (ATS)’s annual international conference, held in Orlando in May 2026, drew over 14,000 participants from more than 100 countries for six days of scientific sessions, clinical trials, and educational programming. The overarching theme was a field in transition — one being reshaped by artificial intelligence and precision medicine, while holding firm
Ayotunde Omitogun, founder of the Cardiac Community in Nigeria, receives prestigious 2026 Rino Aldrighetti Leadership Award by the Pulmonary Hypertension Association (PHA) – June 18, 2026
The Rino Aldrighetti Leadership Award is the highest honor presented by the Pulmonary Hypertension Association (PHA). The award honors people who have shown outstanding leadership, commitment, and worldwide influence in raising PH awareness, supporting patients, and pushing forward treatment options. Omitogun was diagnosed with pulmonary hypertension in 2013 after a congenital heart defect, and over
Liquidia (LQDA) presents new YUTREPIA data at the US Pulmonary Hypertension Association (PHA)s International Annual conference in Dallas, June 11-14, 2026
Earlier this month, Liquidia Corporation presented four posters at the US Pulmonary Hypertension Association (PHA)’s International Conference in Dallas, sharing 24‑week ASCENT study data and broader insights on YUTREPIA (treprostinil) inhalation powder in pulmonary hypertension. Beyond clinical outcomes, the company highlighted patient‑reported cough data, the mental health strain on caregivers and the evolving role of
Efficacy and safety of sotatercept in patients with pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD), ATS international conference, May 18, 2026
New pooled data presented in the form of a scientific poster at the American Thoracic Society 2026 International Conference in Orlando suggests that sotatercept may significantly reduce morbidity and mortality risks in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) — a particularly challenging population to treat. The analysis combined data from three phase
Join the “Global Pulmonary Hypertension Patient Hackathon” organised by the Global Allergy & Airways Patient Platform (GAAPP) and Latin Health Leaders (LDL) on June 10-11, 2026!
Within the framework of the PHA 2026 International Conference (June 11-14 in Dallas, Texas), the Global Allergy & Airways Patient Platform (GAAPP) and Latin Health Leaders (LDL) will convene the “Global Pulmonary Hypertension Patient Hackathon“, taking place on June 10 (full day) and June 11 (half day), with the strategic support of the Pulmonary Vascular Research Institute (PVRI) and the Pulmonary Hypertension
CardioMEMS-guided therapy shows promising results in pulmonary arterial hypertension: ARTISAN interim analysis presented at the American College of Cardiology Congress 2026, March 28–30
One of the most talked-about moments at this year’s American College of Cardiology Scientific Session was the presentation of the ARTISAN interim analysis by Dr. Raymond Benza — a study that was voted one of the Top 4 abstracts in Pulmonary Hypertension. ARTISAN (Afterload Reduction To Improve Right Ventricular Structure And FuNction), is a prospective, multicenter, open-label clinical
René Baumgart Foundation Research Prize 2026 – two awards for groundbreaking pulmonary hypertension research
At the 66th Congress of the German Society for Pneumology in Munich, the €5,000 René Baumgart Foundation research prize was awarded to two outstanding researchers working in the field of pulmonary hypertension (full text in German available at this link) English AI translation and summary Dr. Fenja Knöpp (Justus Liebig University, Giessen) was recognised for
The Alliance for Pulmonary Hypertension participates in the Annual Board Meeting of the European Reference Center for Rare Respiratory Diseases (ERN-LUNG), in Paris, March 23-24, 2026
On 23–24 March 2026, the Alliance for Pulmonary Hypertension attended the Annual Board meeting of ERN-LUNG, the European Reference Network for Rare Respiratory Diseases, in Paris. The Alliance was represented by Louise Bouman, Board member of the organisation and member of the ERN-LUNG E-PAG (European Patient Advisory Group). The meeting brought together healthcare professionals, researchers,
Louise Bouman, Board Member of the Alliance for Pulmonary Hypertension reporting from the PVRI Conference in Dublin, Ireland, 29 January-1st of February, 2026
Louise Bouman attended the Pulmonary Vascular Research Institute conference in Dublin on behalf of the Alliance for Pulmonary Hypertension, of which she is a Board Member. You can find her key highlights summary at this link and the full report below. Louise also attended a “Women in Pulmonary Hypertension” lunch, which you can read about
The Pulmonary Vascular Research Institute (PVRI) 2026 Congress is taking place in Dublin from 28 January-1 February 2026
The Pulmonary Vascular Research Institute (PVRI) Congress 2026 will take place in the historic city of Dublin from 28 January – 1 February 2026. ➡️ Explore the full Congress programme at this link The first and last day (28 January and 1 February) will be satellite meetings with the main plenary sessions happening 29-31 January.
Evolving paradigms in pulmonary hypertension: Highlights of the 6th French Pulmonary Hypertension Network Meeting, Respiratory Medicine and Research, Vol 88, November 2025
The 6th “Journées du Réseau Français de l’Hypertension Pulmonaire” (JRF-HTP), held in October 2024, provided a review of the evolving landscape in pulmonary hypertension (PH). The meeting brought together clinicians and researchers to exchange on the most recent scientific, clinical, and organizational advances in pulmonary hypertension. We are proud that a patient advocate was included as co-author,
Integrating Sotatercept Into Pulmonary Arterial Hypertension (PAH) Care: Vallerie McLaughlin, MD, American Heart Association, November 9, 2025
Vallerie McLaughlin, MD, the Kim A. Eagle M.D. Endowed Professor of Cardiovascular Medicine and Professor of Internal Medicine at the University of Michigan Medical School, presented the results of a pooled analysis of the PULSAR, STELLAR, and ZENITH trials of sotatercept in pulmonary arterial hypertension at the 2025 American Heart Association Scientific Sessions, held in
Mark the date for the National Pulmonary Hypertension Information Day in the Netherlands, November 22, 2025!
🫁 National Pulmonary Hypertension Information Day Date: 22 November 2025 | Time: 10:15 – 16:00Location: Congrescentrum De Schakel, Oranjelaan 10, 3862 CX Nijkerk 📍 Venue: Congrescentrum De Schakel, Nijkerk🎈 Theme: “Stronger Together”🎤 Chair: Arieke van Liere An inspiring day full of information, recognition, and connection—especially for people living with pulmonary hypertension, their loved ones, and
Pulmonary vascular diseases – State of the art session, European Respiratory Society Annual Congress 2025, Septermber 28, 2025
On Monday, 28 September 2025, a State of the Art Session was held at the European Respiratory Society (ERS) Annual Congress 2025 titled: “Pulmonary Hypertension associated with lung diseases: the most burning questions.” The session was chaired by Prof. Dr. Olivier Sitbon, Prof. Dr. David Montani, and Dr. Nesrin Ocal. Leading experts shared the latest
Including the patient voice into pulmonary arterial hypertension (PAH) risk assessment evaluation, a symposium organised by MSD at the ERS Annual Congress, Amsterdam, September 29, 2025
Traditional risk models for pulmonary arterials hypertension rely heavily on objective measures. While essential, they often miss the patient’s lived experience—symptoms, quality-of-life challenges, and life-context factors that shape treatment decisions. At the symposium organised on 29 September 2025 by MSD at the European Respiratory Society Annual Congress in Amsterdam, on the topic of “The Value
Patient empowerment and Patient Reported Outcome Measures (PROMs) highlighted at the “World Symposium on Pulmonary Hypertension Updates” conference, Bologna, July 3-5, 2025
Pisana Ferrari, Secretary General of the Alliance for Pulmonary Hypertension and President of the Italian Pulmonary Hypertension Association AIPI, was invited to deliver the opening presentation on patient perspectives and empowerment at the “World Symposium on Pulmonary Hypertension Updates” conference in Bologna on July 3-5, 2025. Unfortunately, due to health issues, she had to withdraw
How it all started: The Aminorex Epidemic that Launched Systematic Primary Pulmonary Hypertension (PPH) Studies and the First Patient Registry
An article titled “The Genesis and Legacy of the NHLBI Patient Registry for the Characterization of Primary Pulmonary Hypertension”, published recently in Pulmonary Circulation, traces the historical development of primary pulmonary hypertension (PPH) research from its first pathological description by Ernest Romberg in 1891 through the establishment of the landmark US National Heart, Lung, and